Revenue Breakdown
Composition ()
No data
Revenue Streams
Synergy CHC Corp (SNYR) generates its revenue primarily from Nutraceuticals, which accounts for 100.0% of total sales, equivalent to $8.01M. Understanding this concentration is critical for investors evaluating how SNYR navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Synergy CHC Corp maintains a gross margin of 70.50%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.98%, while the net margin is 1.56%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively SNYR converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SNYR competes directly with industry leaders such as NAII and MTEX. With a market capitalization of $21.94M, it holds a significant position in the sector. When comparing efficiency, SNYR's gross margin of 70.50% stands against NAII's 11.65% and MTEX's 76.37%. Such benchmarking helps identify whether Synergy CHC Corp is trading at a premium or discount relative to its financial performance.
